An oral phosphodiesterase 4 inhibitor may offer significant improvement in signs and symptoms of psoriatic arthritis, according to preliminary trial data presented at the American College of Rheumatology annual meeting in Washington.
Researchers at the University of California, San Diego, compared the investigational drug apremilast with placebo. They found that nearly half of the patients with psoriatic arthritis who received 30 mg twice per day saw a 20 percent improvement in sore and swollen joints compared to those who received placebo, MedPage Today reports.
Apremilast was well tolerated, according to the report. Researchers did not observe any opportunistic infections or a higher risk of cardiovascular events. Investigators observed similar adverse events among all groups as a reason for discontinuing treatment.